β-tubulin

Overview

β-tubulin is one of the two major protein subunits that assemble into microtubules, the dynamic cytoskeletal polymers essential for cell shape, intracellular transport, mitosis, and chromosome segregation. In biomedical research, β-tubulin is especially important because many anticancer and antiparasitic agents act by binding to tubulin and altering microtubule dynamics, thereby disrupting cell division or parasite viability.

As a drug target, β-tubulin is commonly studied through its role in tubulin polymerization and in ligand binding at sites such as the colchicine binding site. Modulation of β-tubulin can lead to microtubule network disruption, cell-cycle arrest, and apoptosis. Recent studies have also examined α-tubulin and β-tubulin together in the context of microtubule-targeting compounds, including agents combined with EGFR inhibition, carbonic anhydrase inhibition, Histone deacetylase 6 modulation, or existing therapies such as Caelyx and paclitaxel.

Focus of Latest Publications

Recent publications have focused on β-tubulin as a drug target in both anticancer and herbicidal discovery, with most studies aiming to disrupt microtubule dynamics by inhibiting tubulin polymerization or binding at the colchicine site. Several medicinal chemistry programs designed heterocyclic and hybrid small molecules, including imidazo[1,2-a]pyridines, pyrrolo[2,3-b]pyrazines, pyrazolo[4,3-c]pyridines, quinoxaline-chalcones, and triaryl-tethered acryloyl derivatives, and then assessed their antiproliferative activity alongside direct tubulin assays, docking, and molecular dynamics simulations. Across these studies, the most active compounds consistently caused microtubule network disruption, G2/M cell-cycle arrest, and apoptosis, supporting β-tubulin inhibition as the mechanistic basis for their anticancer effects.

Among the reported anticancer leads, compound 8o from the imidazo[1,2-a]pyridine series showed submicromolar antiproliferative activity and was confirmed to inhibit tubulin polymerization, while compound 10u from the pyrrolo[2,3-b]pyrazine series suppressed tumor growth in an orthotopic Huh7 mouse model without observable systemic toxicity. Similarly, compound 15u from the pyrazolo[4,3-c]pyridine series inhibited tubulin polymerization, disrupted microtubules, and reduced tumor growth in vivo. Other studies identified compound 4i as a potent β-tubulin polymerization inhibitor in hepatocellular carcinoma cells, with apoptosis linked to B-cell lymphoma 2 downregulation and increased Bax and caspase 9 expression, and compound 10v as a covalent colchicine-site inhibitor that bound β-Cys239, overcame drug resistance in MCF-7/ADM cells, and showed better in vivo antitumor efficacy than paclitaxel.

A separate line of work explored dual-target or structure-guided strategies involving β-tubulin. One study developed carboxamide-substituted imidazo[1,2-a]quinoxalines targeting both EGFR and tubulin, with JRC-6 showing microtubule-stabilizing activity comparable to paclitaxel and inducing ROS generation, mitochondrial depolarization, and G2/M arrest. Another reported coumarin-pyrazolo[1,5-a]pyrimidine hybrids with combined carbonic anhydrase and tubulin polymerization inhibition, where compound 13n displayed balanced activity against hCA IX, hCA XII, and tubulin and triggered p53-associated apoptosis. In addition, phenoxy-linked colchicine derivatives were designed to enhance selectivity through added α-tubulin engagement while retaining colchicine-like β-tubulin binding, yielding highly potent compounds with favorable selectivity indices and confirmed microtubule disruption.

Beyond oncology, β-tubulin was also investigated as a target for herbicidal and anthelmintic lead discovery. The plant-derived compound 4-O-α-thevetopyranosyldiphyllin from Taiwania flousiana inhibited tubulin polymerization, bound β-tubulin with high affinity in docking and dynamics studies, and showed broad-spectrum weed control with systemic translocation and crop selectivity. Likewise, xanthone derivatives from Swertia petiolata were evaluated against Haemonchus contortus, and 1-hydroxy-3,5-dimethoxyxanthone showed the strongest in vitro activity with docking support for high-affinity binding to β-tubulin and impairment of microtubule formation. Together, these publications reinforce β-tubulin as a versatile and actively pursued target for microtubule-disrupting agents across cancer, weed management, and antiparasitic research.

Key Publications

• NEWJun Design, synthesis, and biological evaluation of 6-aryl-3-(3,4,5-trimethoxyphenyl)imidazo[1,2-a]pyridine derivatives as novel tubulin inhibitors with potent anticancer efficacy. (Journal of enzyme inhibition and medicinal chemistry, 2026, PMID 42306850): "Tubulin, the fundamental component of microtubules, remains a critical target in anticancer therapy."
• Jun 4-O-α-Thevetopyranosyldiphyllin from Taiwania flousiana: A Novel β-Tubulin Inhibitor with Broad-Spectrum Herbicidal Activity for Sustainable Weed Management. (Journal of agricultural and food chemistry, 2026, PMID 42208048): "These results indicated that 4-O-α-thevetopyranosyldiphyllin was a promising lead compound for the development of a new class of systemic herbicides targeting β-tubulin."
• May Design and Pictet-Spengler enabled synthesis of carboxamide-substituted imidazo[1,2-a]quinoxalines as dual EGFR and tubulin targeting anticancer agents. (Journal of enzyme inhibition and medicinal chemistry, 2026, PMID 42179048): "In this study, we report the Pictet-Spengler enabled synthesis of a series of eighteen carboxamide-substituted imidazo[1,2-a]quinoxaline derivatives (JRC-1-JRC-18) targeting epidermal growth factor receptor (EGFR) and tubulin."
• May Design, Green Synthesis, and Biological Evaluation of Novel Triaryl-Tethered Acryloyl Derivatives as New Generation β-Tubulin Inhibitors for Hepatocellular Carcinoma Treatment. (Drug development research, 2026, PMID 42059208): "Inhibition of β-tubulin polymerization has been set as promising therapeutic strategy for cancer therapy."
• Apr Discovery and biological evaluation of 3-aryl-5-(3,4,5-trimethoxyphenyl)-5H-pyrrolo[2,3-b]pyrazine derivatives as novel tubulin inhibitors with potent anticancer efficacy in vitro and in vivo. (European journal of medicinal chemistry, 2026, PMID 41962330): "As the structural foundation of microtubules, tubulin represents a pivotal molecular target in anticancer drug discovery."
• May Phytochemical profiling and anthelmintic potential of rhizome of Swertia petiolata against Haemonchus contortus: an integrated in vitro and in silico approach. (Veterinary parasitology, 2026, PMID 41946033): "The combined in vitro and in silico findings highlight 1-hydroxy-3,5-dimethoxyxanthone as a promising lead compound targeting β-tubulin and impairs microtubule formation in H. contortus."
• Apr Design, synthesis, and biological evaluation of 6-aryl-1-(3,4,5-trimethoxyphenyl)-1H-pyrazolo[4,3-c]pyridine derivatives targeting the colchicine-binding site as new tubulin inhibitors. (European journal of medicinal chemistry, 2026, PMID 41936799): "Microtubules, dynamic cytoskeletal polymers whose structural subunit is tubulin, represent a well-established target for anticancer drug discovery."
• Jun Multi-target pyrazolopyrimidine-coumarin derivatives as potent CA IX/XII and tubulin polymerization inhibitors: Design, synthesis, and biological evaluation. (European journal of medicinal chemistry, 2026, PMID 41905101): "...designed to target tumor-associated carbonic anhydrases (CA IX/XII) and tubulin polymerization through rational molecular hybridization."
• Mar Synthesis of 2-aryl/alkylaminomethyl 17-sulfamate/17-methyl estratrienes and their in vitro cytotoxicity in human cancer cell cultures. (Steroids, 2026, PMID 41905481): "2-Methoxyestradiol (2-ME), a natural metabolite of 17β-estradiol, exhibits potent anticancer activity by inhibiting tubulin polymerization and modulating steroid sulfatase (STS)."
• Jun Discovery of quinoxaline-chalcone derivatives as covalent colchicine binding site inhibitors for breast and fibrosarcoma treatment. (European journal of medicinal chemistry, 2026, PMID 41889031): "Mechanistic studies demonstrated that 10v inhibited tubulin polymerization and disrupted microtubule network via covalent binding to the colchicine binding site of tubulin."